Genenta Science Future Growth
Future criteria checks 0/6
Genenta Science is forecast to grow earnings and revenue by 58.9% and 63.5% per annum respectively while EPS is expected to grow by 58.5% per annum.
Key information
58.9%
Earnings growth rate
58.5%
EPS growth rate
| Biotechs earnings growth | 26.8% |
| Revenue growth rate | 63.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
We're Keeping An Eye On Genenta Science's (NASDAQ:GNTA) Cash Burn Rate
Jan 26
We're Hopeful That Genenta Science (NASDAQ:GNTA) Will Use Its Cash Wisely
Jul 21We're Not Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn
Dec 10We're Hopeful That Genenta Science (NASDAQ:GNTA) Will Use Its Cash Wisely
Sep 09Gene therapy developer Genenta Science named a buy at Wainwright on tumor approach
Jul 25Is Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?
Mar 18Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 58 | 4 | N/A | N/A | 1 |
| 12/31/2026 | N/A | -20 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -16 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -14 | N/A | N/A | 1 |
| 6/30/2024 | N/A | -9 | -6 | -6 | N/A |
| 3/31/2024 | N/A | -10 | -8 | -8 | N/A |
| 12/31/2023 | N/A | -12 | -11 | -11 | N/A |
| 9/30/2023 | N/A | -12 | -12 | -12 | N/A |
| 6/30/2023 | N/A | -13 | -12 | -12 | N/A |
| 3/31/2023 | N/A | -11 | -10 | -10 | N/A |
| 12/31/2022 | N/A | -8 | -7 | -7 | N/A |
| 9/30/2022 | N/A | -6 | -6 | -6 | N/A |
| 6/30/2022 | N/A | -4 | -5 | -5 | N/A |
| 3/31/2022 | N/A | -5 | -6 | -6 | N/A |
| 12/31/2021 | N/A | -6 | -7 | -7 | N/A |
| 9/30/2021 | N/A | -6 | -8 | -8 | N/A |
| 6/30/2021 | N/A | -7 | -9 | -9 | N/A |
| 3/31/2021 | N/A | -6 | -7 | -7 | N/A |
| 12/31/2020 | N/A | -6 | -6 | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GNTA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GNTA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GNTA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GNTA is forecast to have no revenue next year.
High Growth Revenue: GNTA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GNTA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 15:46 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genenta Science S.p.A. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |
| Emanuela Branchetti | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |